Cargando…
Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells
K-Ras mutations are frequently detected in pancreatic and colon cancers, which are associated with the resistance to MEK inhibitors targeting the Ras pathway. Identifying the underlying mechanisms for the acquired resistance is essential for the future clinical development of MEK inhibitors. Here, w...
Autores principales: | Zhao, Chengguang, Xiao, Hui, Wu, Xiaojuan, Li, Chenglong, Liang, Guang, Yang, Shulin, Lin, Jiayuh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546480/ https://www.ncbi.nlm.nih.gov/pubmed/25961376 |
Ejemplares similares
-
LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy
por: Zuo, Mingxin, et al.
Publicado: (2015) -
MEK targeting in N-RAS mutated metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2014) -
RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
por: Yuan, Xi, et al.
Publicado: (2020) -
K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo
por: Hofmann, Irmgard, et al.
Publicado: (2012) -
L61H46 shows potent efficacy against human pancreatic cancer through inhibiting STAT3 pathway
por: Bai, Encheng, et al.
Publicado: (2018)